Brookline analyst Leah Rush Cann made no change to the firm’s Buy rating and $84 price target on C4 Therapeutics. The timing of FDA-clearance for the CFT8919 IND is as expected, and is supportive of the view that CFT8634 could enter the third-line NSCLC market in 2029, with sales of $1.1B in 2023, the analyst tells investors in a research note. The firm thinks CFT8634 could be C4’s second-largest contributor to revenue in 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CCCC:
- C4 Therapeutics Explodes Higher on Lung Cancer News
- C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
- C4 Therapeutics announces FDA cleared IND application for CFT8919
- C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
- C4 Therapeutics appoints Reyno as Chief Medical Officer